|164.01||+2.65||+1.64%||Vol 721.20K||1Y Perf -21.21%|
|Nov 29th, 2023 16:00 DELAYED|
|- -||- -%|
|Target Price||244.26||Analyst Rating||Moderate Buy 1.68|
|Potential %||48.93||Finscreener Ranking||★★ 45.81|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||+ 37.15|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★ 36.88|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||16.77||Earnings Rating||Strong Buy|
|Market Cap||20.58B||Earnings Date||2nd Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-1.61|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||363.13K|
|Avg. Monthly Volume||538.17K|
|Avg. Quarterly Volume||629.19K|
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) stock closed at 164.01 per share at the end of the most recent trading day (a 1.64% change compared to the prior day closing price) with a volume of 721.20K shares and market capitalization of 20.58B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 1453 people. Alnylam Pharmaceuticals Inc. CEO is John M. Maraganore.
The one-year performance of Alnylam Pharmaceuticals Inc. stock is -21.21%, while year-to-date (YTD) performance is -30.99%. ALNY stock has a five-year performance of 102.08%. Its 52-week range is between 148.1 and 242.97, which gives ALNY stock a 52-week price range ratio of 16.77%
Alnylam Pharmaceuticals Inc. currently has a PE ratio of -23.00, a price-to-book (PB) ratio of 142.92, a price-to-sale (PS) ratio of 38.49, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -36.50%, a ROC of -78.71% and a ROE of -412.82%. The company’s profit margin is -97.99%, its EBITDA margin is -97.30%, and its revenue ttm is $702.38 Million , which makes it $5.71 revenue per share.
Of the last four earnings reports from Alnylam Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.61 for the next earnings report. Alnylam Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Alnylam Pharmaceuticals Inc. is Moderate Buy (1.68), with a target price of $244.26, which is +48.93% compared to the current price. The earnings rating for Alnylam Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Alnylam Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Alnylam Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.77, ATR14 : 5.90, CCI20 : -49.79, Chaikin Money Flow : 0.01, MACD : -1.32, Money Flow Index : 35.38, ROC : -4.75, RSI : 45.15, STOCH (14,3) : 27.69, STOCH RSI : 0.46, UO : 37.42, Williams %R : -72.31), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Alnylam Pharmaceuticals Inc. in the last 12-months were: Akshay K. Vaishnaw (Option Excercise at a value of $2 247 457), Akshay K. Vaishnaw (Sold 44 493 shares of value $9 435 774 ), Amy W. Schulman (Option Excercise at a value of $0), Ausiello Dennis (Option Excercise at a value of $0), Bonney Michael (Option Excercise at a value of $0), Bonney Michael (Sold 6 448 shares of value $1 195 310 ), David E.I. Pyott (Option Excercise at a value of $0), Dennis A. Ausiello (Option Excercise at a value of $0), Fanucci Marsha (Option Excercise at a value of $0), Garg Pushkal (Option Excercise at a value of $241 125), Garg Pushkal (Sold 22 366 shares of value $4 460 850 ), Greenstreet Yvonne (Sold 7 615 shares of value $1 481 811 ), Hamburg Margaret (Option Excercise at a value of $0), Indrani Lall Franchini (Option Excercise at a value of $0), Indrani Lall Franchini (Sold 5 175 shares of value $1 113 562 ), Margaret A. Hamburg (Option Excercise at a value of $0), Marsha H. Fanucci (Option Excercise at a value of $0), Pushkal Garg (Option Excercise at a value of $241 125), Pushkal Garg (Sold 18 072 shares of value $3 614 400 ), Pyott David (Option Excercise at a value of $0), Schulman Amy (Option Excercise at a value of $0), Tanguler Tolga (Option Excercise at a value of $0), Tanguler Tolga (Sold 5 548 shares of value $1 221 563 ), Tolga Tanguler (Option Excercise at a value of $0), Tolga Tanguler (Sold 5 025 shares of value $1 156 692 )
Tue, 07 Nov 2023 13:16 GMT Alnylam Pharma (ALNY) Receives a Hold from Oppenheimer- TipRanks. All rights reserved.
Tue, 10 Oct 2023 17:06 GMT Alnylam Pharma: Rapid Growth and Market Potential in ATTR Sector A Buy Rating Analysis- TipRanks. All rights reserved.
Tue, 10 Oct 2023 09:01 GMT Analysts Are Bullish on These Healthcare Stocks: Alnylam Pharma (ALNY), Reneo Pharmaceuticals (RPHM)- TipRanks. All rights reserved.
Mon, 09 Oct 2023 22:25 GMT Analyst Upholds Buy Rating on Alnylam Pharma Despite FDA Rejection: Future Prospects Remain Promising- TipRanks. All rights reserved.
Fri, 08 Sep 2023 00:45 GMT Alnylam Pharma (ALNY) Receives a Buy from Chardan Capital- TipRanks. All rights reserved.
Fri, 25 Aug 2023 21:03 GMT Alnylam intends to appeal ruling on two patents asserted against Moderna- TipRanks. All rights reserved.
Tue, 25 Jul 2023 12:30 GMT Analysts Top Healthcare Picks: Alnylam Pharma (ALNY), Biogen (BIIB)- TipRanks. All rights reserved.
Tue, 18 Jul 2023 06:45 GMT Alnylam Pharma (ALNY) Gets a Buy from Bernstein- TipRanks. All rights reserved.
Mon, 17 Jul 2023 17:05 GMT Alnylam Pharma (ALNY) Gets a Buy from H.C. Wainwright- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.